Tag: Dermatitis
Reistone Biopharma Co. Ltd. said both doses of the JAK1 inhibitor ivarmacitinib, tested against moderate to severe atopic dermatitis (AD) in a multinational phase III trial, met the study’s co-primary endpoints, delivering significant improvements on a common measure of disease severity vs. placebo. It’s the first National Class A new drug for AD that is […]
The goals of therapy for atopic dermatitis include reducing symptoms of pruritis and dermatitis with disease control and prevention of flares. RR is a 22-year-old female patient presenting to the dermatology clinic. She has a past medical history significant for atopic dermatitis (AD) and eczema. She was treated with steroids in childhood but stopped taking […]
Ruxolitinib cream 1.5% (Opezlura) was approved by the US Food and Drug Administration (FDA) this July for the treatment of nonsegmental vitiligo—a novel, breakthrough indication for a topical JAK inhibitor in a space with few options. Incyte’s agent may be next considered for a chronic skin disease with a more robust armamentarium: atopic dermatitis, which […]
New research shows baricitinib could be an effective treatment option for patients with atopic dermatitis who do not respond to dupilumab. A team, led by Linde de Wijs, Department of Dermatology, Erasmus MC University Medical Center, evaluated the effectiveness and safety of baricitinib treatment in daily practice for patients with atopic dermatitis who have inadequately responded […]